Cancer Cell Patents (Class 424/155.1)
-
Publication number: 20110020430Abstract: Methods for treating neuroblastoma in a subject are provided. The methods include administering to the subject nucleic acid that is capable of causing a significant reduction of the amount of doublecortin like protein (DCL) in the subject. The nucleic acids include antisense oligonucleotides and small interfering RNA.Type: ApplicationFiled: May 24, 2010Publication date: January 27, 2011Applicants: PROSENSA B.V., Universiteit LeidenInventors: Erno VREUGDENHIL, Petra Van Kuik-Romeijn
-
Patent number: 7875278Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.Type: GrantFiled: February 17, 2006Date of Patent: January 25, 2011Assignee: Medarex, Inc.Inventors: Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
-
Patent number: 7871622Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an anchoring domain attached to a second precursor. The first and second precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc.Type: GrantFiled: March 3, 2009Date of Patent: January 18, 2011Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110002887Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: ApplicationFiled: January 13, 2010Publication date: January 6, 2011Applicant: THE UAB RESEARCH FOUNDATIONInventors: Robert P. Kimberly, William J. Koopman, Albert F. LoBuglio, Tong Zhou, Donald J. Buchsbaum, Kimihisa Ichikawa, Jun Ohsumi
-
Patent number: 7862817Abstract: The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.Type: GrantFiled: January 27, 2005Date of Patent: January 4, 2011Assignee: Genentech, Inc.Inventors: Camellia W. Adams, Leonard G. Presta, Mark Sliwkowski
-
Patent number: 7858070Abstract: The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a facile and general way to obtain stably tethered structures of virtually any functionality and/or binding specificity. The stably tethered structures may be administered to subjects for diagnostic and/or therapeutic use, for example for treatment of cancer or autoimmune disease. The stably tethered structures may bind to and/or be conjugated to a variety of known effectors, such as drugs, enzymes, radionuclides, therapeutic agents and/or diagnostic agents.Type: GrantFiled: March 3, 2009Date of Patent: December 28, 2010Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Patent number: 7846441Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.Type: GrantFiled: December 10, 1998Date of Patent: December 7, 2010Assignee: Genentech, Inc.Inventor: Susan D. Hellmann
-
Patent number: 7842292Abstract: The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.Type: GrantFiled: August 9, 2006Date of Patent: November 30, 2010Assignees: Ares Trading S.A., Zymogenetics, Inc., Mayo Foundation for Medical Education and ResearchInventors: Herve Broly, Arnaud Ythier, Eric Sievers, Sharon J. Busby, Jan Öhrström, Ivan Nestorov, Stephen M. Ansell
-
Publication number: 20100297118Abstract: Provided are methods for treating non-small cell lung cancer by administering a therapeutically effective amount of a hedgehog inhibitor.Type: ApplicationFiled: April 16, 2010Publication date: November 25, 2010Inventors: John MacDougall, Kip A. West
-
Patent number: 7837995Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: GrantFiled: December 9, 2002Date of Patent: November 23, 2010Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 7837998Abstract: Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating cancer.Type: GrantFiled: May 20, 2005Date of Patent: November 23, 2010Inventors: Nathaniel Lallatin, Kim L. O'Neill
-
Patent number: 7833528Abstract: Embodiments of the invention relate to a method for treating target cells, tissues or pathogens in a subject, comprising administering a non-covalently bound complex which comprises a multispecific targeting protein and a hapten-enzyme covalent conjugate, followed by administration of a prodrug that is converted to an active drug by the enzyme. Other embodiments of the invention further relate to kits comprising the non-covalently bound complex or the components to prepare the complex.Type: GrantFiled: October 27, 2006Date of Patent: November 16, 2010Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Serengulam V. Govindan, Hans J. Hansen
-
Patent number: 7834155Abstract: Cytotoxic conjugates comprising a cell binding agent and a cytotoxic agent, therapeutic compositions comprising the conjugate, methods for using the conjugates in the inhibition of cell growth and the treatment of disease, and a kit comprising the cytotoxic conjugate are disclosed are all embodiments of the invention. In particular, the cell binding agent is a monoclonal antibody, and epitope-binding fragments thereof, that recognizes and binds the CA6 glycotope. The present invention is also directed to humanized or resurfaced versions of DS6, an anti-CA6 murine monoclonal antibody, and epitope-binding fragments thereof.Type: GrantFiled: August 29, 2005Date of Patent: November 16, 2010Assignee: Immunogen Inc.Inventors: Gillian Payne, Philip Chun, Daniel J. Tavares
-
Publication number: 20100285017Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development.Type: ApplicationFiled: February 7, 2010Publication date: November 11, 2010Inventors: Christian Rohlff, Jonathan Alexander Terrett
-
Patent number: 7829678Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: GrantFiled: November 7, 2008Date of Patent: November 9, 2010Assignee: Neogenix Oncology, Inc.Inventors: J. Andrew Bristol, Judith A. Kantor
-
Patent number: 7820164Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: January 12, 2010Date of Patent: October 26, 2010Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Patent number: 7820787Abstract: The present invention provides antibodies comprising an antigen recognition domain that specifically binds to a metal chelate: mutant antibodies comprising a reactive site not present in the wild-type of the antibody, wherein the reactive site is in a position proximate to or within the antigen recognition domain; and methods of using such antibodies to diagnose and treat disease.Type: GrantFiled: July 22, 2003Date of Patent: October 26, 2010Assignee: The Regents of the University of CaliforniaInventors: Claude F. Meares, Todd M. Corneillie
-
Patent number: 7820170Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: September 28, 2009Date of Patent: October 26, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 7815906Abstract: Methods and compositions for restoring growth inhibition sensitivity to a tumor cell resistant to growth inhibition by HER2 antagonists. The methods involve administering a PCDGF antagonist to the cell in an amount effective to stimulate or restore growth inhibition sensitivity to HER2 antagonists. The invention also provides treatment regimens, and therapeutic compositions comprising an HER2 antagonist and a PCDGF antagonist.Type: GrantFiled: June 18, 2008Date of Patent: October 19, 2010Assignee: A & G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 7811564Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: GrantFiled: January 28, 2004Date of Patent: October 12, 2010Assignee: Proscan RX PharmaInventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffet
-
Patent number: 7811572Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.Type: GrantFiled: August 14, 2006Date of Patent: October 12, 2010Assignee: ImmunoGen, Inc.Inventors: Yong Dai, Yong Wang, Shengjin Jin, Deborah H. Meshulam, Godfrey W. Amphlett
-
Patent number: 7811562Abstract: The present invention provides methods for identifying patients whose cancers are likely to be responsive to IGF1R inhibitory anti-cancer therapy along with methods for treating such patients. Patients identified by a method of the present invention can be treated with any of several known IGF1R inhibitory agents including antibodies, small molecule inhibitors and anti-sense nucleic acids.Type: GrantFiled: November 30, 2005Date of Patent: October 12, 2010Assignee: Schering CorporationInventors: Yan Wang, Jonathan A. Pachter, Yaolin Wang, Ming Liu
-
Patent number: 7807163Abstract: GPR64 antibody compositions are provided. These antibodies may be used for diagnosis or treatment of cancer, especially ovarian cancer, Ewing's sarcoma, uterine cancer, and other GPR64 expressing tumor types.Type: GrantFiled: September 3, 2008Date of Patent: October 5, 2010Assignee: Facet Biotech CorporationInventors: Debbie Law, Qi Wang, Robert DuBridge, Vinay Bhaskar
-
Patent number: 7803372Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.Type: GrantFiled: October 8, 2003Date of Patent: September 28, 2010Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen
-
Patent number: 7803915Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: September 8, 2004Date of Patent: September 28, 2010Assignee: Genentech, Inc.Inventors: Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang, Chie Sakanaka, Anan Chuntharapai, Chae Janeka Reed
-
Patent number: 7803375Abstract: Provided are methods and compositions for treating ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of, for example, a photodynamic therapy (PDT)-based approach can be enhanced by combining the PDT with an anti-FasL factor, for example, an anti-FasL neutralizing antibody.Type: GrantFiled: February 22, 2006Date of Patent: September 28, 2010Assignee: Massachusetts Eye and Ear InfirmaryInventors: Evangelos S. Gragoudas, Vassiliki Poulaki, Joan W. Miller
-
Publication number: 20100239576Abstract: The present invention provides amino ester compounds, salts, and pharmaceutical formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: March 19, 2010Publication date: September 23, 2010Inventor: Ning Xi
-
Patent number: 7799327Abstract: This invention describes a method whereby human autoimmune antibodies are used as carrier compounds to deliver imaging agents and pharmaceutical drugs to the tumor in the human patient. These autoantibodies have the propensity to localize in necrotic areas of tumors but not in healthy normal tissues. By combining various pharmaceutical agents with these carrier proteins it is possible to localize these agents within the necrotic areas of tumors in cancer patients. The carrier proteins may be combined with a variety of imaging agents for detection and diagnosis of tumors, and/or with a variety of radioactive or cytotoxic compounds for cancer treatment.Type: GrantFiled: December 24, 2003Date of Patent: September 21, 2010Inventors: Henry John Smith, James Roger Smith
-
Patent number: 7790165Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: June 8, 2007Date of Patent: September 7, 2010Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Patent number: 7790152Abstract: An enhancer, for treatment of lymphocytic tumors, of an antibody that specifically binds to protein having the amino acid sequence as set forth in SEQ ID NO: 1 and that has a cytotoxic activity, said enhancer comprising a biological response modifier as an active ingredient.Type: GrantFiled: May 2, 2003Date of Patent: September 7, 2010Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masaaki Kosaka, Yasuo Koishihara
-
Patent number: 7790164Abstract: Antibody Fab fragments specific for the EGF receptor are disclosed, as are compositions and kits comprising these Fab proteins. The Fab proteins may be conjugated to drugs or other therapeutic agents or to diagnostic agents. Also disclosed are methods for diagnosing and treating diseases such as tumors and cancer in which cells express high levels of the EGFR, using the foregoing Fab molecules and conjugates.Type: GrantFiled: November 14, 2007Date of Patent: September 7, 2010Assignee: Van Andel Research InstituteInventor: Boliang Cao
-
Patent number: 7790863Abstract: The present invention relates to angiogenesis inhibiting molecules that are the monoclonal antibody H33 or fragments or derivatives thereof, to their use in the treatment of cancer, in particular the treatment of solid tumors and to therapeutic and diagnostic compositions comprising them. The invention relates in particular to humanized derivatives of H33 of human monoclonal antibodies having the specificity of H33.Type: GrantFiled: November 19, 2004Date of Patent: September 7, 2010Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Patent number: 7785590Abstract: The present invention relates generally to antibodies that bind to the Interleukin-13 receptor ?1 chain (IL-13R?1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13R?1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13R?1/ligand interaction is also provided.Type: GrantFiled: May 20, 2004Date of Patent: August 31, 2010Assignee: Zenyth Operations Pty Ltd.Inventors: Felicity Meredith Dunlop, Manuel Baca, Andrew Donald Nash, Louis Jerry Fabri, Douglas James Hilton, Nicos A Nicola
-
Patent number: 7781569Abstract: Compositions and methods for the treatment of cancer, particularly melanoma, myeloma, small cell lung cancer, thymic lymphoma, T-cell lymphoma, B-cell lymphoma, osteosarcoma, and acute T-cell leukemia, are disclosed. Illustrative compositions include one or more anti-ganglioside antibodies and polynucleotides that encode such anti-ganglioside antibodies. These antibodies may be for example, hamster antibodies, chimeric human/hamster antibodies, or humanized antibodies. The disclosed compositions are useful, for example, in the treatment of cancer and can be used to induce apoptosis in a cancer cell.Type: GrantFiled: April 28, 2006Date of Patent: August 24, 2010Assignees: University of Massachusetts, Corixa CorporationInventors: Gary Fanger, Neil Fanger, David John King, Marc W. Retter, Kenneth L. Rock
-
Patent number: 7776311Abstract: The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.Type: GrantFiled: December 18, 2006Date of Patent: August 17, 2010Assignee: Immunomedics, Inc.Inventors: William J. McBride, David M. Goldenberg
-
Publication number: 20100196388Abstract: The invention relates to targeted binding agents against human sonic hedgehog homolog (Shh) and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to Shh. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of Shh and as diagnostics.Type: ApplicationFiled: September 18, 2009Publication date: August 5, 2010Applicant: Medlmmune LLCInventors: David Jenkins, Neil Michaud, Naomi Laing, Jaspal Singh Kang
-
Patent number: 7767417Abstract: The present invention relates to a method of identifying compounds as candidate drugs for treatment of cancer by providing a cell expressing a GTPase protein that is regulated by a prenyl-electrostatic switch, contacting the cell with compounds to be evaluated, and selecting compounds able to regulate charge at the prenyl-electrostatic switch in the GTPase protein as candidate drugs for treatment of cancer. Also disclosed are methods of treating cancer in a patient. An isolated antibody which binds to a phosphorylated prenyl-electrostatic switch on a K-Ras4B protein is also disclosed, as is a kit for detecting phosphorylation of a prenyl-electrostatic switch in a K-Ras4B protein which includes a labeled antibody and a device to detect the label. Also disclosed is a method of detecting phosphorylation of a prenyl-electrostatic switch on a K-Ras4B protein in a biological sample.Type: GrantFiled: April 19, 2005Date of Patent: August 3, 2010Assignee: New York UniversityInventors: Mark R. Philips, Trever G. Bivona
-
Patent number: 7754211Abstract: Novel immunotoxins and methods of treating neoplastic diseases are provided. More specifically, immunotoxins comprised conjugation of a c-erbB-2 targeting moiety and a cell growth modulator are provided. These immunotoxins specifically and selectively kill tumor cells that over-express the c-erbB-2 protein. The novel immunotoxins would be useful in treating human mammary carcinomas, human ovarian carcinomas, lung carcinomas, gastric tumors, salivary gland adenocarcinomas, and colon adenocarcinomas.Type: GrantFiled: October 13, 2004Date of Patent: July 13, 2010Assignee: Research Development FoundationInventors: Michael Rosenblum, Laura K. Shawver
-
Patent number: 7754206Abstract: The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4 (D114). The solid tumor may comprise solid tumor stem cells.Type: GrantFiled: December 1, 2006Date of Patent: July 13, 2010Assignee: The Regents of the University of MichiganInventors: Michael F. Clarke, Max S. Wicha, Muhammad Al-Hajj
-
Patent number: 7750125Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: August 17, 2007Date of Patent: July 6, 2010Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans
-
Patent number: 7749504Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: April 11, 2007Date of Patent: July 6, 2010Assignee: Genentech, Inc.Inventors: Belinda Cairns, Ruihuan Chen, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen, Heidi S. Phillips, Paul Polakis, Susan D. Spencer, Victoria Smith, P. Mickey Williams, Thomas D. Wu, Zemin Zhang
-
Publication number: 20100166751Abstract: The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines.Type: ApplicationFiled: November 9, 2009Publication date: July 1, 2010Applicants: Biopolymer Engineering (d/b/a Biothera), University of Louisville Research Foundation, Inc.Inventors: Gary R. Ostroff, Gordon D. Ross, Trunetta Jo Dockter Ross
-
Patent number: 7744878Abstract: Provided herein is disclosure about the development and characterization of an antibody (mPA7) which binds to antigen CD46 which is present on a variety of human cancers from ovary, breast, lung, prostate, colon, kidney, and pancreas. Methods of diagnosing and treating various cancers by using antibodies such as mPA7 directed against this antigen are also disclosed.Type: GrantFiled: September 19, 2006Date of Patent: June 29, 2010Assignee: Raven biotechnologies, inc.Inventor: Jennie P. Mather
-
Patent number: 7744877Abstract: Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.Type: GrantFiled: September 11, 2002Date of Patent: June 29, 2010Assignee: Biogen Idec Inc.Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Patent number: 7744889Abstract: ??-Unsaturated sulfoxides of Formula I: are useful as antiproliferative agents including, for example, anticancer agents, and as radioprotective and chemoprotective agents.Type: GrantFiled: November 8, 2004Date of Patent: June 29, 2010Assignee: Temple University - Of The Commonwealth System of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy, Stanley C. Bell
-
Patent number: 7745410Abstract: The present invention relates to a bladder tumor-targeting peptide and use thereof. More particularly, the present invention relates to a bladder tumor-targeting peptide having an amino acid sequence represented by SEQ ID NO: 7 and use thereof. The peptide according to the present invention is capable of specific binding to bladder tumor cells in vivo and in vitro. The peptide according to the present invention or an antibody thereof is useful for a marker for the diagnosis of bladder tumors, and for a drug carrier targeting bladder tumor.Type: GrantFiled: November 6, 2007Date of Patent: June 29, 2010Assignees: Kyungpook National University Industry-Academica Cooperation Foundation, Burnham Institute for Medical ResearchInventors: Erkki Ruoslahti, Byung-Heon Lee, In-San Kim
-
Patent number: 7744871Abstract: The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) and of ligands for those receptors. Immunotherapeutic combinations are described that cause the blockade of RTK receptors and/or their ligands, by means of a combination of passive and active immunotherapy. The referenced procedures can be applied to patients in different clinical stages with tumors of epithelial origin that over-express those receptors. The combination of active and passive immunotherapy can be simultaneous or sequential independent of whether the therapeutic procedure will be used in patients with advanced disease or as adjuvant therapy.Type: GrantFiled: April 20, 2006Date of Patent: June 29, 2010Assignee: Centro De Inmunologia MolecularInventors: Rolando Pérex Rodriguez, Gisela Maria González Marinello, Tania Crobet Ramos, Irene Beausoleil Del Gado
-
Publication number: 20100158801Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of isolated monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human hematologic malignancies. The invention further relates to binding assays, which utilize the isolated monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: December 23, 2008Publication date: June 24, 2010Inventors: David S.F. Young, Daniel S. Pereira, John E. Dick
-
Patent number: 7740847Abstract: The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.Type: GrantFiled: July 18, 2005Date of Patent: June 22, 2010Assignee: Applied Molecular Evolution, Inc.Inventors: Barrett Allan, Weidong Jiang, Ying Tang, Jeffry Dean Watkins
-
Publication number: 20100150910Abstract: The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.Type: ApplicationFiled: October 10, 2007Publication date: June 17, 2010Applicant: Universite de NantesInventors: Stéphane Birkle, Jean-Marie Mussini, Jacques Aubry, Jacques Barbet, Jean-Francois Chatal